A comprehensive screening & evaluation platform for various therapeutic modalities

Leveraging over thirty years of experiences in immunology, antibody science, and protein engineering, we have built a comprehensive platform for functional screening, in vitro and in vivo evaluation, and antibody engineering. This robust platform enables us to advance our FIC antibodies into a range of therapeutic modalities, including antibody-drug conjugates (ADCs), Fab and F(ab’)2 fragments, and chimeric antigen receptor (CAR)-T/NK cell therapies, to deliver more effective and safer treatments for different indications.